This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Sector Weekly Rewind


BOSTON ( TheStreet) -- Adam Feuerstein's take on the biotech week that ended Nov. 12, 2010:

The week's best-performing stocks in the sector: Aastrom Biosciences (ASTM) (+48%), AspenBio Pharma (APPY) (+32%), Bionovo (BNVO) (28%), Vermillion (VRML) (+26%) and Genomic Health (GHDX) (+20%).

Is it any coincidence that Aastrom filed a $75 million mixed shelf registration Friday?

Human Genome Sciences (HGSI): FDA Reviews Lupus Drug

The week's worst-performing stocks: Surmodics (SRDX) (-30%), Epicept (EPCT) (-28%), Metabolix (MBLX) (-25%), Angiotech Pharmaceuticals (ANPI) (-21%) and Repros Therapeutics (RPRXD) (-19%).

Cadence Pharmaceuticals (CADX) sold 11.5 million shares at $8, raising $86 million to fund commercial launch of Ofirmev, a hospital-based intravenous form of acetameniphan.

> > Bull or Bear? Vote in Our Poll

Athersys (ATHX) received FDA clearance to start phase II study of Multistem stem cell therapy for inflammatory bowel disease.

Arena Pharma (ARNA): 'Marginal' Obesity Drug Now Unsafe?

Research abstracts for American Society of Hematology annual meeting were posted online.

Cerus (CERS) priced 7.37 million stock units (stock and warrants) at $2.85 a unit, raising $20 million.

FDA cleared Polymedix (PYMX.OB) to begin human clinical trials of antibiotic PMX-30063.

Osiris Therapeutics (OSIR) Drags Feet on U.S. Approval Filing

Dendreon (DNDN) filed for FDA approval of an expansion to its Provenge manufacturing plant in New Jersey, while the Centers for Medicare and Medicaid (CMS) released the technical assessment of Dendreon's Provenge ahead of next week's National Coverage Determination meeting.

Micromet (MITI) sold 9.9 million shares at $7.30, raising $72 million.

This week's Biotech Stock Mailbag: Theratechnologies (TH.TO), Arena Pharmaceuticals, Amarin (AMRN), and Osiris Therapeutics.

A preview of next week's important regulatory meetings facing Human Genome Sciences, Dendreon and MELA Sciences (MELA).

Human Genome: Benlysta FDA Panel Preview

Glaxo (GSK) Lawyer Indicted for Obstructing the FDA (via Pharmalot)

European Drug Approval Agency Looking for new leader (via invivo blog)

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:

Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,656.77 +299.90 1.73%
S&P 500 2,045.29 +32.40 1.61%
NASDAQ 4,722.2680 +77.9560 1.68%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs